



ELSEVIER

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.elsevier.com/locate/rmed

CORRIGENDUM

Corrigendum to “Fluticasone furoate/ vilanterol (100/25; 200/25 μ g) improves lung function in COPD: A randomised trial” [Respir Med 107 (2013) 550–559]



Fernando J. Martinez ^{a,*}, Joseph Boscia ^b, Gregory Feldman ^c,
Catherine Scott-Wilson ^d, Sally Kilbride ^e, Leonardo Fabbri ^f,
Courtney Crim ^e, Peter M.A. Calverley ^g

^a University of Michigan, Ann Arbor, MI, USA

^b CU Pharmaceutical Research, Union, SC, USA

^c S. Carolina Pharmaceutical Research, Spartanburg, SC, USA

^d GlaxoSmithKline, Research Triangle Park, NC, USA

^e GlaxoSmithKline, Stockley Park, London, UK

^f University of Modena and Reggio Emilia Modena, Modena, Italy

^g Respiratory Research Department, University of Liverpool, Liverpool, UK

The authors regret there were errors in the Abstract, ‘Safety evaluation’, Table 1, Table 2 and Figure 1 sections of the above paper.

The errors are shown below.

The authors apologise for any inconvenience caused.

DOI of original article: <http://dx.doi.org/10.1016/j.rmed.2012.12.016>.

* Corresponding author. University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA. Tel.: +1 734 936 4000.

E-mail address: fmartine@med.umich.edu (F.J. Martinez).

0954-6111/\$ - see front matter © 2013 Elsevier Ltd. All rights reserved.

<http://dx.doi.org/10.1016/j.rmed.2013.10.009>

[Location]: current incorrect text printed in article	Text should correctly read
[p. 551, Abstract]: VI 25 µg significantly improved wm and trough FEV ₁ vs. placebo (209 ml and 131 ml, respectively).	VI 25 µg significantly improved wm and trough FEV ₁ vs. placebo (185 ml and 100 ml, respectively).
[p. 552, Safety evaluation]: (<i>n</i> = 406; UC population)	(<i>n</i> = 407; UC population)
[p. 553, Figure 1]: FF/VI 200/25 vs. FF 100	FF/VI 200/25 vs. FF 200
[p. 554, Table 1. SD value for age in FF/VI 200/25 group]: [8.58]	[8.67]
[p. 555, Table 2. Footnote]: CRQ-SAS dyspnoea domain is scaled from 0 to 7, with 0 indicating no impairment	CRQ-SAS dyspnoea domain is scaled from 1 to 7, with 1 indicating no impairment